---
schema_version: "secwatch.filing_event.v1"
accession: "0001214659-26-009469"
form_type: "8-K"
ticker: "ALZN"
cik: "0001677077"
company_name: "Alzamend Neuro, Inc."
filed_at: "2026-08-03T20:30:21+00:00"
generated_at: "2026-08-03T20:31:30.336996+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Alzamend Neuro Enters $25M Securities Purchase Agreement and Reports Nasdaq Non-Compliance

## Summary
- Entered securities purchase agreement with Ault Lending for up to $25M in Series D convertible preferred stock; initial closing of $7.5M on July 31, 2026.
- Notified Nasdaq of non-compliance with majority independent board standard following death of independent director Lynne Fahey McGrath on July 20, 2026; cure period until July 20, 2027.
- Filed Series D Certificate of Designation with Delaware Secretary of State on July 31, 2026.
- Purchaser Ault Lending is an affiliate of the Company; conversion price floor at $0.2668 per share.

## SEC filing metadata
- accession: 0001214659-26-009469
- form_type: 8-K
- ticker: ALZN
- cik: 0001677077
- company_name: Alzamend Neuro, Inc.
- filed_at: 2026-08-03T20:30:21+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.01, 3.01, 3.02, 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1677077/000121465926009469/0001214659-26-009469-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1677077/000121465926009469/az7312618k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001214659-26-009469
- JSON: https://secwatch.observer/filing/0001214659-26-009469.json
- Plain text: https://secwatch.observer/filing/0001214659-26-009469.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.